Your session is about to expire
← Back to Search
Immunotherapy for Recurrent Glioblastoma
Study Summary
This trial studies the effects of pembrolizumab on patients with glioblastoma that has come back. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have a brain tumor that has come back after initial treatment and needs to be removed surgically within 4 to 6 weeks.
- Group 1: Treatment (pembrolizumab, surgery)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has Pembrolizumab received regulatory approval from the FDA?
"Our evaluation of pembrolizumab's safety landed it a score of 2, as there is evidence that supports its security but no proof that attests to its efficacy."
Is there currently an open enrollment period for this experiment?
"According to clinicaltrials.gov, the protocol for this study is no longer recruiting participants after being posted on April 28th 2015 and last edited on February 3rd 2022. Despite its inactivity, there are 2353 other trials that have opened their doors to volunteers at present."
What maladies are most often treated with Pembrolizumab?
"In medicine, Pembrolizumab is often prescribed for malignant neoplasms. It also can be beneficial in treating unresectable melanoma, as well as mitigating chemotherapy-induced disease progression or microsatellite instability high conditions."
Could you provide me with a summary of the prior research conducted surrounding Pembrolizumab?
"Currently, there are 961 active clinical trials scrutinizing the effects of Pembrolizumab and 122 of those studies are at Phase 3. The majority of these research initiatives take place in Houston but other sites across 35731 locations also conduct investigations concerning this drug."
What is the enrollment capacity of this research study?
"At present, this medical trial is not in the process of recruiting patients. It was first published on April 28th 2015 and last edited on February 3rd 2022. If you are researching other trials, there are 1392 gliosarcoma studies and 961 Pembrolizumab experiments actively enrolling participants."
Share this study with friends
Copy Link
Messenger